Compare General Motors Company (GM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Vertex Pharmaceuticals Incorporated — how do they compare? General Motors Company trades at $89.5 (market cap $76.85B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and General Motors Company pays a 0.82% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| GM | VRTX | |
|---|---|---|
Market Cap | $76.85B | $132.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $529.65 |
52-Week Low | $54.16 | $376.62 |
Enterprise Value | $179.83B | $126.92B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $87.58, up 0.74% today, showing strong technical momentum with a bullish moving average signal and support at $87. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.57 beating expectations of $3.19. Recent developments include the renewal of GM's China joint venture with SAIC for 20 years and expansion of EV charging infrastructure with Pilot and EVgo.
GM presents a compelling investment case with analyst consensus price target of $108.82 (24% upside), strong institutional support (65% buy ratings), and improving cash flow trends. However, risks include declining profit margins (1.05% net margin in 2025), rising debt levels, and competitive pressures in the EV transition. The stock offers value with attractive valuation multiples (P/S 0.44, P/B 1.24) but requires monitoring of margin sustainability.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
